Janux Therapeutics Inc — Quarterly Financial Statistics (NASDAQ:JANX) | MetaTrader

Open full chart

Financials

Overview Relevé Statistics Dividends

Quarterly Annual

Cash from operating activities 2.23 M16.73 M17.02 M23.81 M12.86 M28.54 M 82.23 M Cash from investing activities -12.67 M-33.93 M340.39 M-1.56 M-8.31 M-29.54 M 300.98 M Cash from financing activities 1.65 M386.65 M554 K954 K493 K2.94 M 4.95 M Free cash flow 2.21 M16.68 M16.65 M23.34 M12.76 M28.44 M 81.19 M

Nouvelles

Janux therapeutics doses first participant in JANX011 phase 1 trial

Vir Biotechnology Stock: The Low-Down On The Readouts Ahead (NASDAQ:VIR)

Wall Street Analysts See a 319.23% Upside in Janux Therapeutics (JANX): Can the Stock Really Move This High?

Janux Therapeutics nomme William Go au poste de directeur médical

Janux Therapeutics appoints William Go as new chief medical officer

Bristol-Myers Squibb: Solid Tumor Collaboration With Janux And Camzyos Expansion (BMY)

JANX Enters Global Oncology Collaboration With BMY, Stock Rises

Janux Therapeutics conclut un accord biotechnologique avec Bristol Myers d'une valeur de 800 millions de dollars | Benzinga France

L’action de Janux grimpe après un accord de collaboration avec Bristol Myers Squibb

Janux stock rises after Bristol Myers Squibb collaboration deal

Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million - Janux Therapeutics (NASDAQ:JANX)

L’action de Janux Therapeutics s’envole après sa collaboration avec Bristol Myers Squibb